0001193125-20-217104.txt : 20200812 0001193125-20-217104.hdr.sgml : 20200812 20200812084654 ACCESSION NUMBER: 0001193125-20-217104 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200812 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200812 DATE AS OF CHANGE: 20200812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 201094252 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d87775d8k.htm 8-K 8-K
CVS HEALTH Corp false 0000064803 0000064803 2020-08-12 2020-08-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2020

 

 

 

LOGO

CVS HEALTH CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-01011   05-0494040

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

One CVS Drive, Woonsocket, Rhode Island   02895
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (401) 765-1500

Former name or former address, if changed since last report: N/A

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.01 per share   CVS   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Section 8 - Other Events

 

Item 8.01.

Other Events

On August 12, 2020, CVS Health Corporation issued a press release announcing the commencement of cash tender offers for (i) up to $3,000,000,000 aggregate principal amount of its 4.000% Senior Notes due 2023 and 3.700% Senior Notes due 2023 and the 2.800% Senior Notes due 2023 issued by its wholly-owned subsidiary, Aetna Inc. and (ii) up to $3,000,000,000 aggregate principal amount of its 4.100% Senior Notes due 2025 and 3.875% Senior Notes due 2025. A copy of the press release is attached hereto as Exhibit 99.1.

Section 9 - Financial Statements and Exhibits

 

Item 9.01

Financial Statements and Exhibits.

(d)    Exhibits.

The exhibits to this Current Report on Form 8-K are as follows:

INDEX TO EXHIBITS

 

Exhibit

   

Description

99.1    Press Release of CVS Health Corporation dated August 12, 2020
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      CVS HEALTH CORPORATION
Date: August 12, 2020     By:  

/s/ Colleen M. McIntosh

      Colleen M. McIntosh
      Senior Vice President, Chief Governance Officer and Corporate Secretary
 EX-99.1 2 d87775dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Investor    Valerie Haertel    Media    T.J. Crawford
Contact:    Senior Vice President    Contact:    Vice President
   Investor Relations       External Affairs
   (401) 770-4050       (212) 457-0583

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Cash Tender Offers

for Certain Outstanding Notes

WOONSOCKET, RI, August 12, 2020 – CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today that it has commenced cash tender offers (each, a “Tender Offer” and collectively, the “Tender Offers”) for (i) up to $3,000,000,000 aggregate principal amount (the “2023 Notes Maximum Amount”) of its 4.000% Senior Notes due 2023 and 3.700% Senior Notes due 2023 and the 2.800% Senior Notes due 2023 issued by its wholly-owned subsidiary, Aetna Inc. (collectively, the “2023 Notes”) in the priorities set forth in the first table below (the “2023 Notes Tender Offers”) and (ii) up to $3,000,000,000 aggregate principal amount (the “2025 Notes Maximum Amount” and, together with the 2023 Notes Maximum Amount, the “Maximum Amounts”) of its 4.100% Senior Notes due 2025 and 3.875% Senior Notes due 2025 (collectively, the “2025 Notes”, and, together with the 2023 Notes, the “Notes”) in the priorities set forth in the second table below (the “2025 Notes Tender Offers”). Each group of Tender Offers that constitutes either the 2023 Notes Tender Offers or the 2025 Notes Tender Offers as the “Capped Tender Offers”.

The Tender Offers are summarized in the tables below:

The 2023 Notes Tender Offers

 

Title of Notes

   CUSIP
Number		     Original
Issuer		     Principal
Amount
Outstanding		     2023 Notes
Maximum
Amount(1)(2)		     Acceptance
Priority
Level(3)		   UST
Reference
Security		   Bloomberg
Reference
Page(4)		   Fixed
Spread
(bps)		   Early
Tender
Payment(5)

4.000% Senior Notes due 2023

     126650 CC2       CVS Health     $ 1,250,000,000     $ 3,000,000,000     1   0.125% UST due
07/15/2023		   PX1   20   $30

3.700% Senior Notes due 2023

     126650 CV0       CVS Health     $ 6,000,000,000     2   0.125% UST due
07/15/2023		   PX1   25   $30

2.800% Senior Notes due 2023

     00817Y AV0       Aetna Inc.     $ 1,300,000,000     3   0.125% UST due
07/15/2023		   PX1   25   $30

The 2025 Notes Tender Offers

 

Title of Notes

   CUSIP
Number		     Original
Issuer		     Principal
Amount
Outstanding		     2025 Notes
Maximum
Amount (1)(2)		     Acceptance
Priority
Level(3)		   UST
Reference
Security		   Bloomberg
Reference
Page(4)		   Fixed
Spread
(bps)		   Early
Tender
Payment(5)

4.100% Senior Notes due 2025

     126650 CW8       CVS Health     $ 5,000,000,000     $ 3,000,000,000     1   0.250% UST due
07/31/2025		   PX1   36   $30

3.875% Senior Notes due 2025

     126650 CL2       CVS Health     $ 2,828,067,000     2   0.250% UST due
07/31/2025		   PX1   43   $30

 

(1)

The 2023 Notes Maximum Amount of $3,000,000,000 represents the aggregate principal amount of 2023 Notes that will be purchased in the 2023 Notes Tender Offers. The 2025 Notes Maximum Amount of $3,000,000,000 represents the aggregate principal amount of 2025 Notes that will be purchased in the 2025 Notes Tender Offers.

(2)

If the principal amount of Notes tendered at or prior to the Early Tender Date (as defined below) or Expiration Date (as defined below) is such that the Maximum Amount with respect to one of the Capped Tender Offers is not met and the Maximum Amount with respect to the other of the Capped Tender Offers is exceeded, then the Maximum Amount that was exceeded may, at CVS Health’s sole discretion, be increased above such Maximum Amount to allow for the purchase of additional amounts of such Notes provided that aggregate principal amount of $6,000,000,000 of Notes to be purchased in the Tender Offers is not exceeded.

(3)

Subject to the Aggregate Maximum Amount, the Maximum Amounts, Reallocation (as defined below) and proration, the principal amount of each series of Notes that is purchased in each of the Tender Offers will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column.

(4)

The applicable page on Bloomberg from which the Dealer Managers (as defined below) will quote the bid side prices of the applicable U.S. Treasury Security. In the above table, “UST” denotes a U.S. Treasury Security.

(5)

Per $1,000 principal amount of Notes validly tendered at or prior to the Early Tender Date and accepted for purchase.

The Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated August 12, 2020 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a detailed description of the Tender Offers. The Tender Offers are open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Notes. The purpose of the Tender Offers is to refinance a portion of CVS Health’s debt and to lower its overall indebtedness.

The sum of the 2023 Notes Maximum Amount and the 2025 Notes Maximum Amount is $6,000,000,000 (the “Aggregate Maximum Amount”), which represents the aggregate principal amount of the Notes subject to the Tender Offers and excludes any Accrued Interest (as defined below) or Early Tender Payment specified in the tables above that may be payable. If the principal amount of Notes tendered at or prior to the Early Tender Date or Expiration Date is such that the Maximum Amount with respect to one of the Capped Tender Offers is not met and the Maximum Amount with respect to the other of the Capped Tender Offers is exceeded, then the Maximum Amount that was exceeded may, at CVS Health’s sole discretion, be increased above such Maximum Amount to allow for the purchase of additional amounts of such Notes provided that the Aggregate Maximum Amount is not exceeded (“Reallocation”). If the Maximum Amount with respect to one of the Capped Tender Offers is increased at the Early Settlement Date (as defined below) pursuant to a Reallocation and the Aggregate Maximum Amount is not purchased at the Early Settlement Date, CVS Health reserves the right to further adjust the Maximum Amounts for one or both of the Capped Tender Offers in connection with purchases made at the Expiration Date as it deems appropriate provided that the Aggregate Maximum Amount is not exceeded.

The Notes validly tendered and not validly withdrawn at or prior to 5:00 p.m., New York City time, on August 25, 2020 (the “Early Tender Date”) will be eligible to receive the applicable Total Consideration, which includes the Early Tender Payment. The Notes validly tendered after the Early Tender Date but at or prior to 11:59 p.m., New York City time, on September 9, 2020 (the “Expiration Date”) will be eligible to receive the applicable tender offer consideration (the “Maximum Tender Offer Consideration”), namely the applicable Total Consideration minus the Early Tender Payment.

The applicable Total Consideration payable by CVS Health for the Notes will be a price per $1,000 principal amount based on the yield to maturity or first par call date, as the case may be, of the U.S. Treasury reference securities specified in the tables above (the “UST Reference Security”), as determined at 9:00 a.m., New York City time, on August 26, 2020 (unless otherwise extended by us as described in the Offer to Purchase), plus a fixed spread, calculated in accordance with the Offer to Purchase. For the avoidance of doubt, if the applicable Total Consideration determined is less than $1,000 per $1,000 principal amount of such series of Notes, then the Total Consideration will be calculated to the stated maturity date and not to the first par call date for such series of Notes.

The settlement date for the Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date and accepted for purchase is expected to be promptly after the Early Tender Date, which is expected to be August 27, 2020, the second business day after the Early Tender Date (the “Early Settlement Date”). The settlement date for the Notes validly tendered after the Early Tender Date but at or prior to the Expiration Date and accepted for purchase is expected to be September 11, 2020, the second business day after the Expiration Date (the “Final Settlement Date,” and along with the Early Settlement Date, each a “Settlement Date”), if either or both of the Maximum Amounts of applicable Notes is not purchased on such Early Settlement Date.

In addition to the Total Consideration or Maximum Tender Offer Consideration, as applicable, Holders of Notes accepted for purchase will receive accrued and unpaid interest (“Accrued Interest”) on those Notes from the last interest payment date with respect to those Notes to, but not including, the applicable Settlement Date.

Holders who tender their Notes at or prior to 5:00 p.m., New York City time, on August 25, 2020 (such date and time, as it may be extended, the “Withdrawal Deadline”) may withdraw such tendered Notes at any time at or prior to the Withdrawal Deadline. Following the Withdrawal Deadline, Holders who have tendered their Notes (whether before, on or after the Withdrawal Deadline) may not withdraw such Notes unless CVS Health is required to extend withdrawal rights under applicable law.

 

2

CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to terminate the Tender Offers at any time prior to the Expiration Date. The Tender Offers are not conditioned on any minimum principal amount of Notes being tendered but the Tender Offers are subject to a financing condition and certain other general conditions as described in the Offer to Purchase. Each Tender Offer is a separate offer. The Capped Tender Offers are not conditioned on each other. Each Tender Offer may be individually amended, extended or terminated by CVS Health.

CVS Health has retained Barclays Capital Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC to act as Dealer Managers for the Tender Offers. D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Tender Offers. Requests for assistance relating to the procedures for tendering Notes may be directed to the Tender and Information Agent either by email at cvs@dfking.com, or by phone (212) 269-5550 (for banks and brokers only) or (800) 714-3305 (for all others toll free). Requests for assistance relating to the terms and conditions of the Tender Offers may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect), Goldman Sachs & Co. LLC at (800) 828-3182 (toll free) or (212) 902-6351 (collect) or J.P. Morgan Securities LLC at (866) 834-4666 (toll free) or (212) 834-8553 (collect). Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, the Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase made available to Holders of the Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Notes in response to the Tender Offers. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Notes in the Tender Offers, and, if so, the principal amount of Notes to tender.

About CVS Health

CVS Health employees are united around a common goal of becoming the most consumer-centric health company. We’re evolving based on changing consumer needs and meeting people where they are, whether that’s in the community at one of our nearly 10,000 local touchpoints, in the home, or in the palm of their hand. Our newest offerings — from HealthHUB® locations that are redefining what a pharmacy can be, to innovative programs that help manage chronic conditions — are designed to create a higher-quality, simpler and more affordable experience. Learn more about how we’re transforming health at www.cvshealth.com.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties related to the COVID-19 pandemic, the geographies impacted and the severity and duration of the pandemic, the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns, and the timing, scope and impact of stimulus legislation and other federal, state and local governmental responses to the pandemic, as well as the risks and uncertainties described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 and our recently filed Current Reports on Form 8-K.

 

3

You are cautioned not to place undue reliance on CVS Health’s forward looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

 

4

EX-101.SCH 3 cvs-20200812.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cvs-20200812_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cvs-20200812_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g87775g27f51.jpg GRAPHIC begin 644 g87775g27f51.jpg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end XML 7 d87775d8k_htm.xml IDEA: XBRL DOCUMENT 0000064803 2020-08-12 2020-08-12 CVS HEALTH Corp false 0000064803 8-K 2020-08-12 DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 (401) 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Aug. 12, 2020
Cover [Abstract]  
Entity Registrant Name CVS HEALTH Corp
Amendment Flag false
Entity Central Index Key 0000064803
Document Type 8-K
Document Period End Date Aug. 12, 2020
Entity Incorporation State Country Code DE
Entity File Number 001-01011
Entity Tax Identification Number 05-0494040
Entity Address, Address Line One One CVS Drive
Entity Address, City or Town Woonsocket
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02895
City Area Code (401)
Local Phone Number 765-1500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol CVS
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d87775d8k.htm cvs-20200812.xsd cvs-20200812_lab.xml cvs-20200812_pre.xml d87775dex991.htm g87775g27f51.jpg http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d87775d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d87775d8k.htm" ] }, "labelLink": { "local": [ "cvs-20200812_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cvs-20200812_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cvs-20200812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20200812", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d87775d8k.htm", "contextRef": "duration_2020-08-12_to_2020-08-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d87775d8k.htm", "contextRef": "duration_2020-08-12_to_2020-08-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-20-217104-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-217104-xbrl.zip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